Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL8392416 | 0.92 | CA1 (0.50) | CA1CA2TSHRCALM1ARG2 | |
| SCHEMBL25377641 | 0.88 | CA1 (0.46) | CA1CA2TSHRCALM1ARG2 | |
| Pyridine SCHEMBL1581039 | 0.88 | CA1 (0.46) | CA1CA2TSHRARG2TDP1 | |
| SCHEMBL28433271 | 0.86 | CA1 (0.45) | CA1CA2TSHRCALM1ARG2 | |
| SCHEMBL257595 | 0.85 | CA1 (0.50) | CA1CA2TSHRIDO1ALDH1A1 | |
| Dipyridyl SCHEMBL1897600 | 0.82 | KDM4E (0.56) | CA1CA2TSHRTDP1ALDH1A1 | |
| Bromide SCHEMBL5053706 | 0.81 | NOTUM (0.52) | CA1CA2HSD17B10 | |
| SCHEMBL29194264 | 0.80 | ENPP2 (0.43) | CA1CA2ALDH1A1ENPP2ALOX12 | |
| SCHEMBL28946029 | 0.79 | LMNA (0.63) | MAOB | |
| SCHEMBL12030986 | 0.79 | AGXT (0.50) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624275-B1 | Temperature-resistant and salt-tolerant in-situ plugging enhanced gel compositions, gels, preparation methods and applications | CHINA UNIVERSITY OF PETROLEUM-BEIJING (CN) | 2026-05-12 | — | — | US | claimed |
| CN-119144968-A | Method for preparing 4,4' -biphenol compound by electrochemical method | 万华化学集团股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024254448-A2 | BORONATE PRODRUG NANOFORMULATIONS IN DISEASE TREATMENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024172224-A1 | METHOD FOR PRODUCING PH-SENSITIVE MATERIAL, AND ECO-FRIENDLY BATTERY INCLUDING PH-SENSITIVE MATERIAL PRODUCED THEREBY | 한국기계연구원 | 2024-08-22 | — | — | WO | claimed |
| CN-117986594-A | Synthesis method of solid polyboronic acid ester | 无锡琛鹏科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117343090-A | Chemiluminescent probe, preparation method thereof and application thereof in biological imaging | 湖南大学 | 2024-01-05 | — | — | CN | claimed |
| CN-116478199-A | Bimetallic catalyst and preparation method thereof, and preparation method of high molecular weight olefin polymer | 万华化学集团股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-116023209-A | Synthesis method of intermediate and process for preparing bifonazole | 重庆西南制药二厂有限责任公司 | 2023-04-28 | — | — | CN | claimed |
| CN-114644646-A | Near-infrared fluorescent probe with benzylboronic acid pinacol esters as detection groups and preparation method and application thereof | 西北工业大学 | 2022-06-21 | — | — | CN | claimed |
| US-10640592-B2 | Cation polymer capable of removing positive charges through oxidative response, a preparation method and application | ZHEJIANG UNIVERSITY (CN) | 2020-05-05 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1996040652-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| US-5559110-A | HIV ANTIVIRAL, GOOD SYSTEMIC ABSORPTION ADMINISTERED BY MOUTH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-24 | — | — | US | claimed |
| US-5543517-A | VIRICIDES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| US-5532357-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | claimed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1994022840-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624275-B1 | Temperature-resistant and salt-tolerant in-situ plugging enhanced gel compositions, gels, preparation methods and applications | SAV1, MYD88, SMCHD1 | CA1 998/4885CA2 401/4885TSHR 2036/4885 |
| US-10640592-B2 | Cation polymer capable of removing positive charges through oxidative response, a preparation method and application | SLC7A1, PBRM1, PHAX | CA1 3065/4885CA2 366/4885TSHR 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.